The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Andrew J. Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX; Plus Therapeutics
Honoraria - Vascular Biogenics
Consulting or Advisory Role - Alamab Therapeutics; NanoTX; Plus Therapeutics; Vascular Biogenics
Research Funding - Gilead Sciences (Inst); Immunomedics (Inst); Plus Therapeutics (Inst); Upsher-Smith (Inst)
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Frances Valdes
Honoraria - Adverum; Allegro Diagnostics; Allergan; BVI; Genentech; Janssen; Novartis; Santen; Valeant Pharmaceuticals International
Research Funding - Merck; Roche
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Novartis
Research Funding - AstraZeneca; Bayer
 
Jason S. Starr
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Natera; Pfizer; Taiho Oncology; Tersera
Research Funding - Incyte (Inst); Leap Therapeutics; Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Rafael Pharmaceuticals (Inst); Vedanta Biosciences (Inst)
 
Joshua Pelham
Employment - Molecular Templates
 
Thomas Strack
Employment - Molecular Templates
 
Amy Yuet
Employment - Molecular Templates
 
Diana Yurewicz
Employment - Molecular Templates
 
Taunya J. Smith
No Relationships to Disclose
 
Andres Machado
Consulting or Advisory Role - Eisai; Lilly
Research Funding - Eisai; Genentech; Lilly; Merrimack; Millennium; Novartis; Pfizer; Seagen; Tempus
Other Relationship - Taiho Oncology
 
William Jeffery Edenfield
Consulting or Advisory Role - Chimerix
 
Aki Morikawa
Consulting or Advisory Role - Eisai; Lilly; Seagen
Research Funding - Eisai (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Tempus (Inst)
Other Relationship - Taiho Pharmaceutical
 
Meena Okera
No Relationships to Disclose
 
Nihal E. Abdulla
No Relationships to Disclose
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck